CPS Technologies Posts Q2 2026 Earnings and $9.6M Capital Raise; CAMP4 Therapeutics Secures $50.1M Private Placement

CPS Technologies Corp. reported fiscal second‑quarter 2026 revenue of $8.3 million, a slight increase from the prior year, and a gross margin of 14.8 %. The company posted an operating loss of $0.2 million after a profit in the comparable period. It completed a secondary offering that generated $9.6 million in gross proceeds, which will support growth initiatives, including a controlled‑fragmentation tungsten warhead program for the U.S. Army and a weight‑reduction project for the U.S. Navy’s Amphibious Combat Vehicle.

CAMP4 Therapeutics Corporation announced the second closing of its $100 million private placement, receiving $50.1 million in gross proceeds. The funds will be used to advance CMP‑002, a regulatory RNA‑targeting therapy for SYNGAP1‑related disorder, and to support the company’s broader early‑stage pipeline. The placement involved institutional investors such as Coastlands Capital and Janus Henderson, with lead placement agent Leerink Partners. The securities were sold in a private transaction not registered under the U.S. Securities Act.